Ventyx biosciences announces positive top-line data from its phase 2a safety and biomarker trial evaluating vtx3232 in patients with early-stage parkinson's disease

The study met its primary goal of establishing safety and tolerability of vtx3232 in patients with early-stage parkinson's disease

VTYX Ratings Summary

VTYX Quant Ranking